Profound Medical (PROF) to Release Earnings on Thursday

Profound Medical (NASDAQ:PROF - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data after the market closes on Thursday, May 8th. Analysts expect Profound Medical to post earnings of ($0.29) per share and revenue of $4.78 million for the quarter.

Profound Medical (NASDAQ:PROF - Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.11. The business had revenue of $4.18 million for the quarter, compared to analyst estimates of $5.92 million. Profound Medical had a negative return on equity of 85.22% and a negative net margin of 349.41%. On average, analysts expect Profound Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Profound Medical Stock Down 4.5 %

Shares of PROF traded down $0.24 during mid-day trading on Tuesday, hitting $5.23. 20,024 shares of the company's stock were exchanged, compared to its average volume of 59,840. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.12 and a quick ratio of 5.16. Profound Medical has a 52 week low of $3.90 and a 52 week high of $11.42. The company has a market cap of $157.06 million, a PE ratio of -3.90 and a beta of 0.44. The company has a 50-day simple moving average of $5.75 and a 200 day simple moving average of $6.80.

Analyst Ratings Changes

Separately, Lake Street Capital lowered their price target on shares of Profound Medical from $17.00 to $11.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.